Pediatrik Miyelodisplastik Sendromunda Kök Hücre Nakli

Miyelodisplastik sendromlar inefektif hematopoez,lösemi gelişme riski ile karakterize klonal heterojen bir hastalık grubudur. Çocuklarda nadiren görülür.Yakın zamanda yapılan sınıflamada 3 ana hastalık tanımlamaktadır: Jüvenil miyelomonositik lösemi (JMML),Down sendromunun miyeloid lösemisi (MDS,geçici miyeloproliferatif hastalık, ve akut miyeloid lösemi) ve MDS. Hematopoietik kök hücre nakli tek tedavi seçeneği olup, kür %60 olarak bildirilmiştir.

Hematopoietic Stem Cell Transplantation in Pediatric Myelodysplastic Syndromes

Myelodysplastic syndromes (MDSs) are a heterogenous group of hemopoietic clonal disorders characterized by ineffective hemopoiesis and frequent evolution to leukemia.They are rare entities, particularly in children.Recently,they have been classified into 3 major groups: MDS, juvenile myelomonocytic leukemia, and Down syndrome–associated myeloid leukemia.Haematopoietic stem cell transplantation(HSCT) is the treatment of choice and results in cure rates of around 60%.

___

  • Niemeyer CM, Kratz CP, Hasle H. Pediatric myelodysplastic syndromes. Curr Treat Options Oncol. 2005; 6:209-14.
  • Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003; 17:277-82.
  • Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revisionof the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114:937-51.
  • Mandel K, Dror Y, Poon Y Freedman MH.. A practical,comprehensive classification for pediatric myelodysplastic syndromes:the CCC system. J Pediatr Hematol Oncol. 2002; 24:596-605.
  • Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120:2454-65.
  • Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997; 89:3534-43. Niemeyer CM, Kratz CP. Pediatric myelodysplastic syndromes and and juvenile myelomonocytic leukemia:Molecular classification and treatment options. Br J Hematol. 2008; 140:610-24. Pinkel D. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood. 1998; 91:365-7.
  • Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005; 105:410-9.
  • Locatelli F, Niemeyer C, Angelucci E, Bender-Götze C, Burdach S, Ebell W et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol. 1997; 15:566